Review Policy

The 6th International Current Breakthrough in Pharmacy (ICB-Pharma) 2025 implements a peer-review policy of double-blind review, where each paper will be evaluated and reviewed. The Track Editor and Reviewer will evaluate the submitted paper to determine its suitability for the conference focus and scope.

Once the paper is submitted, it will be sent to two independent expert reviewers (with one extra expert reviewer, if needed). Their role is to review and recommend whether the paper is suitable enough to be accepted for presentation and recommended for publication in journal. After going through all these processes, author can submit to the target journal independently with by attaching a letter of recommendation from the ICB Pharma 6 committee.The submission, review, and APC payment processes follow the mechanisms of each journal.

For International Journal of Applied Pharmaceutics (IJAP), article and APC payment will be submitted collectively to journal through the ICB Pharma 6 committee.